BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 28753826)

  • 1. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Positivity Associated With Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma.
    Smith ME; Farahani SJ; Chao T; Palmer M; Arriola A; Lal P
    Am J Clin Pathol; 2020 Nov; 154(6):802-810. PubMed ID: 32864684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated With Higher Pathologic Stage.
    Ward M; Albertson D; Furtado LV; Deftereos G
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):56-61. PubMed ID: 34183505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
    Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
    Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
    Gulinac M; Dikov D; Velikova T; Belovezhdov V
    Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
    Bellmunt J; Mullane SA; Werner L; Fay AP; Callea M; Leow JJ; Taplin ME; Choueiri TK; Hodi FS; Freeman GJ; Signoretti S
    Ann Oncol; 2015 Apr; 26(4):812-817. PubMed ID: 25600565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
    Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Perrone F; Nicolai N; Catanzaro M; Biasoni D; Torelli T; Piva L; Stagni S; Salvioni R; Mariani L; Colecchia M
    Clin Genitourin Cancer; 2018 Apr; 16(2):e403-e410. PubMed ID: 29111177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
    Tomiyama E; Fujita K; Rodriguez Pena MDC; Taheri D; Banno E; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Yamaguchi S; Fushimi H; Yoshimura K; Uemura H; Netto GJ; Nonomura N
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
    Campedel L; Seisen T; Cussenot O; Comperat E; Varinot J; RouprĂȘt M; Cancel-Tassin G
    Prog Urol; 2018 Dec; 28(16):900-905. PubMed ID: 30219646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Okuda Y; Kato T; Fujita K; Fushimi H; Miyamoto H; Netto GJ; Nonomura N
    Cancer Genomics Proteomics; 2024; 21(2):137-143. PubMed ID: 38423597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 expression in upper tract urothelial carcinoma associates with adverse clinicopathological features and poor survival.
    Koyama Y; Morikawa T; Miyama Y; Miyakawa J; Kawai T; Kume H; Sawabe M; Ushiku T
    Pathol Res Pract; 2020 Dec; 216(12):153219. PubMed ID: 33049447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma.
    Arriola AGP; Farahani SJ; Bhargava HK; Guzzo TJ; Brooks JSJ; Lal P
    Am J Clin Pathol; 2019 May; 151(6):561-573. PubMed ID: 30776071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
    Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
    Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.
    Chen CH; Tsai MY; Chiang PC; Sung MT; Luo HL; Suen JL; Tsai EM; Chiang PH
    Cancer Immunol Immunother; 2021 Oct; 70(10):2981-2990. PubMed ID: 33740124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
    Krabbe LM; Heitplatz B; Preuss S; Hutchinson RC; Woldu SL; Singla N; Boegemann M; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Rapoport LM; Glybochko PV; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Xylinas E; Margulis V
    J Urol; 2017 Dec; 198(6):1253-1262. PubMed ID: 28668287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
    Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
    Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
    Zhang B; Yu W; Feng X; Zhao Z; Fan Y; Meng Y; Hu S; Cui Y; He Q; Zhang H; Li D; He Z; Zhou L; Jin J; Han W
    Med Oncol; 2017 May; 34(5):94. PubMed ID: 28409437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma.
    Krabbe LM; Bagrodia A; Lotan Y; Gayed BA; Darwish OM; Youssef RF; John G; Harrow B; Jacobs C; Gaitonde M; Sagalowsky AI; Shariat SF; Kapur P; Margulis V
    J Urol; 2014 Jan; 191(1):28-34. PubMed ID: 23871758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.